Dichotomy of protective cellular immune responses to human visceral leishmaniasis

Clinical and Experimental Immunology

Volumn 140, Issue 2, 2005, Pages 349-353

  Khalil, E A G ^a   Ayed, N B ^a   Musa, A M ^a   Ibrahim, M E ^a   Mukhtar, M M ^a   Zijlstra, E E ^a,e   Elhassan, I M ^a   Smith, P G ^b   Kieny, P M ^c   Ghalib, H W ^c   Zicker, F ^c   Modabber, F ^d,f   Elhassan, A M ^a  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Infectious Diseases Research Institute   (United States)

^e UNIVERSITY OF MALAWI   (Malawi)

^f NONE   (France)

Author keywords

Dichotomy; Human visceral leishmaniasis; Immune responses

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 5; LEISHMANIA ANTIBODY; LEISHMANIA VACCINE; PARASITE ANTIGEN; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INJECTION SITE REACTION; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIN SKIN TEST; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN INDURATION; SKIN LEISHMANIASIS; SKIN TEST; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-5; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS, VISCERAL; MALE; MYCOBACTERIUM BOVIS; PROTOZOAN VACCINES; SKIN TESTS;

EID: 20244377212     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02768.x     Document Type: Article

References (22)

1. Ibrahim ME, Evans DA, Theander TG, El-Hassan AM, Kharazmi A. Diversity among Leishmania isolates from the Sudan: isoenzyme homogeneity of L. donovani versus heterogeneity of L. major. Trans R Soc Trop Med Hyg 1995; 89:366-9.
2. Elnaiem DE, Schorscher J, Bendall A et al. Risk mapping of visceral leishmaniasis: the role of local variation in rainfall and altitude on the presence and incidence of kala-azar in eastern Sudan. Am J Trop Med Hyg 2003; 68:10-17.
3. El-Hassan AM, Zijlstra EE. Leishmaniasis in Sudan. Trans R Soc Trop Med Hyg 2001; 95 (Suppl. 1):S27-58.
4. el Amin EM, Wright EP, Vlug A. Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class- and subclass-specific reagents. Clin Exp Immunol 1986; 64 (1):14-19.
5. Kumar P, Pai K, Tripathi K, Pandey HP, Sundar S. Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis. Clin Diag Lab Immunol 2002; 9:1119-23.
6. Ghalib HW, Piuvezam MR, Skeiky YA et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92:324-9.
7. Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Ismail A, Theander TG. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 2000; 119:523-9.
8. Kharazmi A, Kemp K, Ismail A et al. T-cell response in human leishmaniasis. Immunol Lett 1999; 65:105-8.
9. Kemp M, Kurtzhals JA, Bendtzen K et al. Lieshmania donovani-reactive Th1 and Th2-like T-cells clones from individuals who have recovered from visceral lieshmaniasis. Infect Immun 1993b; 61:1069-73.
10. Zijlstra EE, El-Hassan AM, Ismail A, Ghalib HW. Endemic Kalaazar in eastern Sudan: a longitudinal study of the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1994; 51:826-36.
11. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993; 5:524-31.
12. Khalil EAG, El-Hassan AM, Zijlstra EE et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356:1565-9.
13. Khalil EAG, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages an endemic area in endemic area in eastern Sudan. Trop Med Int Health 2002; 7:35-44.
14. Kamil AA, Khalil EAG, Musa AM et al. Alum-precipitated autoclaved L. major plus BCG, a candidate vaccine for visceral leishmaniasis: safety, skin delayed hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97:365-8.
15. Momeni AZ, Jalayer T, Emamjomeh M et al. A randomized double-blind, controlled trial of killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17:466-72.
16. Antunes CM, Mayrink W, Magalhaes PA et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 1986; 15:572-80.
17. Zijlstra EE, El-Hassan AM. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar. Trans R Soc Trop Med Hyg 1993; 4:425-7.
18. Satti IN, Osman HY, Daifalla NS et al. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001; 19:2100-6.
19. Satti I, El-Hassan AM, Khalil EAG, Akuffo H. The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers. Trans R Soc Trop Med Hyg 2002; 96:565-7.
20. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31:2848-56.
21. Musa AM, Khalil EAG, Raheem MA et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 2002; 96:765-72.
22. Sharifi I, Fekri AR, Aflatonian MR et al. Double-blind randomized controlled vaccine trial of a single dose of killed Leishmania major plus BGG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351:1540-3.